Neonatal drug development

Early Human Development

Volumn 87, Issue 11, 2011, Pages 763-768

  Turner, Mark A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Development; Drug; Medicine; Neonatal

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE PERSONNEL; NEONATAL DRUG DEVELOPMENT; NEWBORN CARE; PARENT; PATENT DUCTUS ARTERIOSUS; PRESCRIPTION; TOTAL QUALITY MANAGEMENT; TREATMENT PLANNING;

BIOLOGICAL MARKERS; DRUG DESIGN; DRUG EVALUATION; DRUG INDUSTRY; DRUG TOLERANCE; HUMANS; INFANT, NEWBORN; MARKETING OF HEALTH SERVICES; PHARMACEUTICAL PREPARATIONS; RESEARCH DESIGN;

EID: 80054950146     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2011.08.014     Document Type: Article

References (16)

1. Mulberg A.E., Silber S.A., van den Anker J.N. Pediatric drug development: concepts and applications 2009, John Wiley, Hoboken, New Jersey, USA.
2. Benitz W.E. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?. J Perinatol 2010, 30:241-252.
3. Dempsey E.M., Barrington K.J. Evaluation and treatment of hypotension in the preterm infant. Clin Perinatol 2009, 36:75-85.
4. Lass J., Kaar R., Jogi K., Varendi H., Metsvaht T., Lutsar I. Drug utilisation pattern and off-label use of medicines in Estonian neonatal units. Eur J Clin Pharmacol 2011, Jun 11. [Epub ahead of print].
5. Turner M.A., Lewis S., Hawcutt D.B., Field D. Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey. BMC Pediatr 2009, 9:50.
6. Suyagh M., Collier P.S., Millership J.S., Iheagwaram G., Millar M., Halliday H.L., et al. Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. Pediatrics 2011, 127:e367-e374.
7. Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies (2008/C 243/01) Accessed 21st August 2011, at. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2008:243:0001:0012:EN:PDF.
8. Pritchard J.F., Jurima-Romet M., Reimer M.L., Mortimer E., Rolfe B., Cayen M.N. Making better drugs: decision gates in non-clinical drug development. Nat Rev Drug Discov 2003, 2:542-553.
9. McKenna S.P. Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science. BMC Med 2011, 9:86.
10. Biomakers in drug development: a handbook of practice, applications and strategy 2010, John Wiley, Hoboken, New Jersey, USA. M.B. Bleavins, C. Carini, M. Jurima-Romet, R. Rahbart (Eds.).
11. Clinical Studies Groups Accessed 29th July 2011, at. http://www.mcrn.org.uk/index.php?option=com_content&view=article&id=71&Itemid=68.
12. Note for guidance on general consideration for clinical trials Accessed 29th July 2011, at. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002877.pdf.
13. Orphan designation Accessed 21st August 2011, at. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac05800240ce.
14. Bonati M., Pandolfini C. Off-label drug use in children should be rational. Arch Dis Child 2011, 96:870-871.
15. Turner M.A., Jacqz-Aigrain E., Kotecha S. Azithromycin, ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development. Arch Dis Child 2011, Jun 22. [Epub ahead of print].
16. Hirt D., Van Overmeire B., Treluyer J.M., Langhendries J.P., Marguglio A., Eisinger M.J., et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol 2008, 65:629-636.